Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
Alessio Fiascarelli(Menarini Group (Italy)), Monica Binaschi(Menarini Group (Italy))
Cited by 10
Related Papers
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
|Breast Cancer Research and Treatment|2023|6